Conversations with Oncology Investigators: Bridging the Gap between Research and Patient Care


GastricCancerUpdate117

Interview with Peter C Enzinger, MD

Track 1: FLOT4-AIO: Results of a Phase III trial evaluating the effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction (GEJ) carcinoma
Track 2: Perspective on the results of KEYNOTE-059 Cohort 1: Efficacy and safety of pembrolizumab monotherapy in patients with previously treated gastric cancer
Track 3: Activity of anti-PD-1 antibodies alone or in combination with ipilimumab for advanced gastroesophageal cancers
Track 4: MSI testing for patients with gastric cancer
Track 5: Incorporation of anti-PD-1 immune checkpoint inhibitors into the therapeutic algorithm for advanced gastric cancer
Track 6: Comparison of neoadjuvant chemotherapy regimens for locally advanced esophageal cancer
Track 7: Results of the Phase II FAST study: Progression-free and overall survival advantage with the addition of the anti-CLDN18.2 antibody claudiximab (IMAB362) to epirubicin/oxaliplatin/capecitabine as first-line therapy for patients with advanced CLDN18.2-positive gastric and GEJ adenocarcinoma
Track 8: Status of the Phase III BRIGHTER trial evaluating weekly paclitaxel with or without napabucasin (BBI608) for previously treated advanced gastric or GEJ adenocarcinoma
Track 9: Case: A 72-year-old man with previously treated metastatic gastric cancer receives ramucirumab/paclitaxel
Track 10: Angiogenesis inhibitors in gastric cancer
Track 11: RAINFALL: A Phase III trial of cisplatin/fluoropyrimidine with or without ramucirumab as first-line therapy for metastatic gastric or GEJ adenocarcinoma
Track 12: Incidence of pseudoprogression with the use of immune checkpoint inhibition in gastric cancer
Track 13: Checkpoint inhibitor-associated autoimmune toxicities
Track 14: Case: A 58-year-old man presents with HER2-positive GEJ cancer and receives CAPOX with bevacizumab and trastuzumab on a clinical trial
Track 15: Perspective on anti-angiogenic therapy
Track 16: Phase I/II trial of the anti-HER2 monoclonal antibody margetuximab in combination with pembrolizumab for relapsed/refractory advanced HER2-positive gastric or GEJ cancer
Track 17: Second-line therapy options for patients with metastatic gastroesophageal cancer
Track 18: Activity of anti-PD-1 checkpoint inhibitors for recurrent or metastatic gastric or GEJ adenocarcinoma

Interview with Yelena Y Janjigian, MD

Track 1: Case: A 47-year-old man with heavily pretreated advanced gastric cancer experiences a prolonged response with nivolumab and ipilimumab on the Phase I/II CheckMate 032 trial
Track 2: Incidence of microsatellite instability (MSI)-high tumors in advanced gastroesophageal cancer
Track 3: Results of CheckMate 032: Efficacy and tolerability of nivolumab alone or in combination with ipilimumab for advanced chemotherapy-refractory gastric, esophageal or GEJ cancer
Track 4: Perspective on duration of immune checkpoint inhibitor therapy
Track 5: Ongoing investigations of immune checkpoint inhibitors in the (neo)adjuvant setting
Track 6: Sequencing of chemotherapeutic regimens and immune checkpoint inhibitors for metastatic gastric cancer
Track 7: Case: A 52-year-old woman with MSI-high, Stage IV GEJ adenocarcinoma
Track 8: Case: A 60-year-old man with HER2-positive GEJ adenocarcinoma and liver and lung metastases
Track 9: Case: A 62-year-old woman with metastatic gastric cancer previously treated with FOLFOX who is now receiving ramucirumab/paclitaxel
Track 10: Case: A 70-year-old woman with metastatic gastric adenocarcinoma and a history of congestive heart failure
Track 11: New agents on the horizon in gastric cancer
Track 12: Case: A 68-year-old woman with locally advanced gastric adenocarcinoma
 
FACULTY:
 
Peter C Enzinger, MD
Director
Center for Esophageal and
Gastric Cancer
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
 
Yelena Y Janjigian, MD
Assistant Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
 
EDITOR:
Neil Love, MD
Research To Practice
Miami, Florida